Additionally, the 36-month beta value for PDSB is 1.87. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PDSB is 36.02M and currently, short sellers hold a 11.42% ratio of that float. The average trading volume of PDSB on January 31, 2025 was 396.40K shares.
PDSB) stock’s latest price update
The stock price of PDS Biotechnology Corporation (NASDAQ: PDSB) has jumped by 9.21 compared to previous close of 1.52. Despite this, the company has seen a gain of 9.93% in its stock price over the last five trading days. globenewswire.com reported 2024-12-06 that PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech’s 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech.
PDSB’s Market Performance
PDSB’s stock has risen by 9.93% in the past week, with a monthly drop of -2.92% and a quarterly drop of -49.70%. The volatility ratio for the week is 8.37% while the volatility levels for the last 30 days are 9.15% for PDS Biotechnology Corporation The simple moving average for the past 20 days is 6.99% for PDSB’s stock, with a -42.72% simple moving average for the past 200 days.
Analysts’ Opinion of PDSB
Many brokerage firms have already submitted their reports for PDSB stocks, with B. Riley Securities repeating the rating for PDSB by listing it as a “Buy.” The predicted price for PDSB in the upcoming period, according to B. Riley Securities is $10 based on the research report published on November 01, 2022 of the previous year 2022.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see PDSB reach a price target of $25. The rating they have provided for PDSB stocks is “Overweight” according to the report published on June 28th, 2021.
H.C. Wainwright gave a rating of “Buy” to PDSB, setting the target price at $6 in the report published on November 10th of the previous year.
PDSB Trading at -8.31% from the 50-Day Moving Average
After a stumble in the market that brought PDSB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.15% of loss for the given period.
Volatility was left at 9.15%, however, over the last 30 days, the volatility rate increased by 8.37%, as shares sank -1.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.22% lower at present.
During the last 5 trading sessions, PDSB rose by +9.93%, which changed the moving average for the period of 200-days by -47.96% in comparison to the 20-day moving average, which settled at $1.5515. In addition, PDS Biotechnology Corporation saw 1.84% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PDSB
The total capital return value is set at -1.15. Equity return is now at value -174.49, with -73.98 for asset returns.
Based on PDS Biotechnology Corporation (PDSB), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -1.43. The debt to equity ratio resting at 1.12. The interest coverage ratio of the stock is -8.28.
Currently, EBITDA for the company is -40.08 million with net debt to EBITDA at 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.84.
Conclusion
In conclusion, PDS Biotechnology Corporation (PDSB) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
